Incyte Corp. (INCY) Reports Positive Results from Phase IIa Trials of Topical JAK Inhibitor

September 18, 2008 8:12 AM EDT

Incyte Corporation (Nasdaq: INCY) reported positive results from two 28-day Phase IIa clinical trials of topical INCB18424, a selective janus-associated kinase inhibitor, in patients with mild to moderate psoriasis. Results from the first study (Study 201), a Phase IIa dose-escalation trial involving 28 patients, demonstrated that INCB18424 was well tolerated at all doses and significantly improved overall total lesion score and each component of the total lesion score as compared to vehicle. In this trial, INCB18424 at 1.5% twice daily also showed improvements in total lesion scores that were similar to the currently approved therapies, Dovenex(R) and Diprolene(R).

The second study (Study 202) is an ongoing open-label sub-total inunction 28-day Phase IIa trial designed to evaluate the safety and pharmacokinetics of INCB18424 at increasing coverage levels of total body surface area. Results from Study 202 demonstrated that INCB18424 was well tolerated in the first cohort of patients involving five subjects who applied the compound to not less than 2% or more than 7% of their BSA. Data from the first cohort of this trial also showed that INCB18424 improved lesion thickness, erythema and scaling, and reduced overall treated lesion area as compared to the overall untreated lesions.

Incyte Corporation operates as a drug discovery and development company, which focuses on developing proprietary small molecule drugs to treat human immunodeficiency virus (HIV), diabetes, oncology, and inflammation diseases.

Related Categories

Corporate News

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?